Forecast

There is no analyst data available for this company.

News Go to news feed

Hapvida Q1 2026: profitability improves as loss ratio falls

Hapvida reports a marked improvement in the loss ratio to 72.2% in Q1 2026 and an adjusted EBITDA of R$803m (margin 10.2%), indicating successful measures to control medical costs. Despite a decline of 44,500 insured individuals to 8.68 million, revenue remained stable at R$7,892m and adjusted net income rose to R$244m. Administrative expenses and legal disputes weighed on the cost structure, while free cash flow was robust at R$443m. Management is pursuing a five‑pillar turnaround focused on rational growth, network expansion, AI and capital discipline; analysts expect a return to profitability in 2026. » More on de.investing.com
Hapvida: Q4‑2025 profit falls 65% amid increased customer churn

Hapvida reports an adjusted net profit decline of 64.9% in Q4 2025 to R$181m on a 5.9% rise in net revenue to R$7.915bn. Adjusted EBITDA fell 32.8% and the EBITDA margin dropped 520 basis points to 9.0%, while the cash‑MLR rose to 75.5%. On an organic basis the company lost 140,000 health plan members, mainly in the Southeast and South, and free cash flow was negative R$233m. Net debt increased to R$5.183bn and management announced a six‑pillar turnaround plan focused on customer retention, cost discipline and strengthening technology. » More on de.investing.com
Hapvida Q3 2025: revenue rises, EBITDA falls on higher medical loss ratio

Hapvida reported net revenue of R$ 7,775 million in Q3 2025 (+6% y/y), but missed analyst expectations. The Cash Medical Loss Ratio rose to 75.2%, driven by higher hospital and emergency usage, which pushed adjusted EBITDA down to R$ 746 million (-17.6% q/q) and the EBITDA margin to 9.6%. Adjusted net income rose to R$ 338 million, while the stock fell sharply, losing about 33%. Management expects rate adjustments of around 10% by year-end and relies on network expansion and technology use to improve margins. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, HAPVIDA PARTICIPAÇÕES E INVESTIMENTOS has already paid €0.013 in dividends. The last payout was in January 2022.

Financials

In the last quarter, HAPVIDA PARTICIPAÇÕES E INVESTIMENTOS had revenue of €206.32M and net profit of -€12.91M

(EUR)	June 2026	YoY
Revenue	206.32M	83.41%
Gross profit	161.41M	58.62%
Net profit	-12.91M	75.07%
EBITDA	63.23M	46.29%

Fundamentals

Metric	Value
Market capitalization	€578.75M
Number of shares	475.06M
52-week high/low	€7.00 - €1.01
Dividends	No
Beta	0.26
P/E ratio	-19.62
PEG ratio	0.05
P/B ratio	0.07
P/S ratio	0.19

Company profile

Hapvida Participações e Investimentos S.A. ist zusammen mit ihren Tochtergesellschaften im Gesundheitssektor in Brasilien tätig. Das Unternehmen bietet Kranken- und Zahnversicherungen an. Es bietet auch medizinische und paramedizinische, Labor-, Diagnose-, Bildgebungs- und Ultraschalldienste an und organisiert Kurse, Vorträge, Seminare und andere Veranstaltungen. Darüber hinaus beschäftigt sich das Unternehmen mit der Verwaltung, Beratung und Implementierung von Betriebssystemen für private Gesundheitsvorsorgepläne im Dentalbereich, der Verwaltung, Beratung, Implementierung und dem Verkauf von individuellen, familiären und kollektiven Gesundheitssystemen und -plänen sowie der Erstattung von medizinischen, zahnmedizinischen, Krankenhaus- und Gesundheitskosten an seine Begünstigten und bietet Gesundheitsassistenzdienste an. Das Unternehmen betreibt ein Netzwerk von 47 Krankenhäusern, 47 Notfallstationen, 199 Kliniken und 172 Diagnosezentren. Das Unternehmen wurde 1979 gegründet und hat seinen Hauptsitz in Fortaleza, Brasilien. Hapvida Participações e Investimentos S.A. ist als Tochtergesellschaft von PPAR Pinheiro Participações S.A. tätig.